For the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME) who have previously responded to at least 2 intravitreal injections of a vascular endothelial growth factor (VEGF) inhibitor.1
SUSVIMO Surgical Excellence Educational Events
Genentech is pleased to offer you the opportunity to expand your knowledge of SUSVIMO with peer-led surgical education and refresher courses.
Thursday, May 8, 2025
9:30 PM ET | 6:30 PM PT
VIRTUAL PROGRAM
Surgical Excellence from SUSVIMO
Margaret Amy Chang, MD
Retinal Consultants Medical Group
Sacramento, CA
Register
Thursday, May 22, 2025
7:00 PM ET | 4:00 PM PT
VIRTUAL PROGRAM
Surgical Excellence from SUSVIMO
Carl Awh, MD
Tennessee Retina
Nashville, TN
Register

Important Safety Information

  • Ocular or periocular infections
  • Active intraocular inflammation
  • Hypersensitivity
  • The SUSVIMO implant and/or implant-related procedures have been associated with endophthalmitis, rhegmatogenous retinal detachment, implant dislocation, septum dislodgement, vitreous hemorrhage, conjunctival erosion, conjunctival retraction, and conjunctival blebs. Patients should be instructed to report any signs or symptoms that could be associated with these events without delay. Additional surgical and/or medical management may be required
  • Vitreous hemorrhage: Temporarily discontinue antithrombotic medication prior to the implant insertion procedure to reduce the risk of vitreous hemorrhage. Vitrectomy may be needed
  • Postoperative decrease in visual acuity: A decrease in visual acuity usually occurs over the first 2 postoperative months

The most common adverse reactions (≥10%) were conjunctival hemorrhage, conjunctival hyperemia, iritis, eye pain, conjunctival disorder, cataract, and vitreous hemorrhage.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see additional Important Safety Information in the full SUSVIMO Prescribing Information, including BOXED WARNING.

REFERENCES: 1. SUSVIMO [package insert]. South San Francisco, CA: Genentech, Inc; 2025.